trending Market Intelligence /marketintelligence/en/news-insights/trending/yuWzvMmXeYRPEp__-yta9w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

Novo Nordisk A/S said the U.S. Food and Drug Administration approved a label expansion for the company's blockbuster diabetes drug Ozempic.

The U.S. regulator granted the label expansion to the injectable drug for reducing the risk of major adverse cardiovascular events — including cardiovascular death, nonfatal heart attack or nonfatal stroke — in adults with type 2 diabetes and established cardiovascular disease.

The approval was supported by results of a phase 3 trial called Sustain 6, in which Ozempic reduced the risk of major adverse heart events by 21% compared to placebo, according to a Jan. 16 news release.

The U.S. FDA first approved Ozempic in 2017 to improve glycemic control in adults with type 2 diabetes. Ozempic is also approved in the EU and Japan, among other territories.

SNL Image